FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Furie

Research Profile

Disorders

Chemicals & Drugs

Procedures

Double-Blind Method

Concepts & Ideas

Anatomy

Co-author Network

Publications

TOP 3
J Mosak; Richard Furie
Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Kenneth C Kalunian; Kyriakos A Kirou; Elena M Massarotti; Chaim Putterman; Rosalind Ramsey-Goldman; Joyce Reyes-Thomas; Emily Somers; Jill P Buyon; W Winn Chatham; Puja Chitkara; Thierry Dervieux; Richard Furie; Rachel L Gross; Cole Harris; Christine Hsieh; Arthur Weinstein
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Joseph Mosak; Richard Furie
Comparative safety of therapies in systemic lupus erythematosus.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Furie (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: J Mosak; Richard Furie
Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Lupus 2013;22(4):361-71.
2012: Kenneth C Kalunian; Kyriakos A Kirou; Elena M Massarotti; Chaim Putterman; Rosalind Ramsey-Goldman; Joyce Reyes-Thomas; Emily Somers; Jill P Buyon; W Winn Chatham; Puja Chitkara; Thierry Dervieux; Richard Furie; Rachel L Gross; Cole Harris; Christine Hsieh; Arthur Weinstein
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Arthritis and rheumatism 2012;64(12):4040-7.
2012: Joseph Mosak; Richard Furie
Comparative safety of therapies in systemic lupus erythematosus.
Rheumatic diseases clinics of North America 2012;38(4):795-807.
2012: Susan Manzi; Joan T Merrill; Sandra V Navarra; Michelle Petri; Jorge Sánchez-Guerrero; Z John Zhong; Simon Cooper; David P D'Cruz; Andrea Doria; William Freimuth; Richard Furie; Ellen M Ginzler; Dafna Gladman; Douglas Hough
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
Annals of the rheumatic diseases 2012;71(11):1833-8.
2012: Diane Lewis Horowitz; Richard Furie
Belimumab is approved by the FDA: what more do we need to know to optimize decision making?
Current rheumatology reports 2012;14(4):318-23.
2012: Brad H Rovin; Jorge Sanchez-Guerrero; David Zhang; Gerald Appel; Paul Brunetta; Fernando C Fervenza; Richard Furie; Jay P Garg; Kevin Latinis; R John Looney; Romeo Maciuca
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Arthritis and rheumatism 2012;64(4):1215-26.
2011: Richard Furie; Ellen M Ginzler; Douglas R Hough; Joan T Merrill; Michelle Petri; Jorge Sanchez-Guerrero; Andreas Schwarting; William Stohl; Dana Tegzová; Ronald F van Vollenhoven; Daniel J Wallace; Omid Zamani; Z John Zhong; Ricard Cervera; Winn Chatham; William Freimuth
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Arthritis and rheumatism 2011;63(12):3918-30.
2011: Ariela Arad; VALERIE PROULLE; Richard Furie; Barbara C Furie; Bruce Furie
β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.
Blood 2011;117(12):3453-9.
2010: Annett M Jacobi; Weiqing Huang; Tao Wang; William Freimuth; Inaki Sanz; Richard Furie; Meggan Mackay; Cynthia Aranow; Betty Diamond; Anne Davidson
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
Arthritis and rheumatism 2010;62(1):201-10.
2009: Richard Furie; Michelle Petri; Daniel J Wallace; Ellen M Ginzler; Joan T Merrill; William Stohl; W Winn Chatham; Vibeke Strand; Arthur Weinstein; Marc R Chevrier; Z John Zhong; William W Freimuth
Novel evidence-based systemic lupus erythematosus responder index.
Arthritis and rheumatism 2009;61(9):1143-51.
2009: Daniel J Wallace; William Stohl; Richard Furie; Jeffrey R Lisse; James D McKay; Joan T Merrill; Michelle Petri; Ellen M Ginzler; W Winn Chatham; W Joseph McCune; Vivian Fernandez; Marc R Chevrier; Z John Zhong; William W Freimuth
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Arthritis and rheumatism 2009;61(9):1168-78.
2009: Maria-Louise Barilla-LaBarca; James C Tsang; Melissa Goldsmith; Richard Furie
Design, implementation, and outcome of a hands-on arthrocentesis workshop.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2009;15(6):275-9.
2009: Diane M Horowitz; Richard Furie
Abetimus sodium: a medication for the prevention of lupus nephritis flares.
Expert opinion on pharmacotherapy 2009;10(9):1501-7.
2009: Pralay K Sarkar; Nick Patel; Richard Furie; Arunabh Talwar
Pulmonary manifestations of primary Sjögren's syndrome.
The Indian journal of chest diseases & allied sciences 2009;51(2):93-101.
2008: Chunyu Liu; Franak Batliwalla; Wentian Li; Annette Lee; Ronenn Roubenoff; Evan Beckman; Houman Khalili; Aarti Damle; Marlena Kern; Richard Furie; Josée Dupuis; Robert M Plenge; Marieke Coenen; timothy wayne behrens; John P Carulli; Peter K Gregersen
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis.
Molecular medicine (Cambridge, Mass.) 2008;14(9-10):575-81.
2008: Mario H Cardiel; James Tumlin; Richard Furie; Daniel J Wallace; Tenshang Joh; Matthew D Linnik
Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
Arthritis and rheumatism 2008;58(8):2470-80.
2008: Jorge Sánchez-Guerrero; Hilda E Fragoso-Loyo; C Michael Neuwelt; Daniel J Wallace; Ellen M Ginzler; Yvonne R S Sherrer; Harris H McIlwain; Pamela G Freeman; Cynthia Aranow; Michelle Petri; Atulya A Deodhar; Ellen Blanton; Susan Manzi; Arthur Kavanaugh; Jeffrey R Lisse; Rosalind Ramsey-Goldman; James D McKay; Alan J Kivitz; Philip J Mease; Anne E Winkler; Leslie E Kahl; Albert H Lee; Richard Furie; C Vibeke Strand; Lillian Lou; Mumtaz Ahmed; Betty Quarles; Kenneth E Schwartz
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
The Journal of rheumatology 2008;35(8):1567-75.
2008: Edward C Keystone; G R Burmester; Richard Furie; J E Loveless; P Emery; J Kremer; P P Tak; M S Broder; E Yu; M Cravets; F Magrini; F Jost
Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.
Arthritis and rheumatism 2008;59(6):785-93.
2008: Richard Furie; William Stohl; Ellen M Ginzler; Michael Becker; Nilamadhab Mishra; Winn Chatham; Joan T Merrill; Arthur Weinstein; W Joseph McCune; John Zhong; Wendy Cai; William Freimuth
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Arthritis research & therapy 2008;10(5):R109.
2006: Stanley B Cohen; Paul Emery; Maria W Greenwald; Maxime Dougados; Richard Furie; Mark C Genovese; Edward C Keystone; James E Loveless; Gerd R Burmester; Matthew W Cravets; Eva W Hessey; Timothy Shaw; Mark C Totoritis
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Arthritis and rheumatism 2006;54(9):2793-806.
2006: Richard Furie
Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus.
Rheumatic diseases clinics of North America 2006;32(1):149-56, x.
2005: Franak M Batliwalla; Emily C Baechler; Xiangli Xiao; Wentian Li; S Balasubramanian; Houman Khalili; Aarti Damle; Ward A Ortmann; A Perrone; A B Kantor; Pércio S Gulko; Michael J Kern; Richard Furie; timothy wayne behrens; Peter K Gregersen
Peripheral blood gene expression profiling in rheumatoid arthritis.
Genes and immunity 2005;6(5):388-97.
2005: Dorothy Guzowski; Alamelu Chandrasekaran; Craig Gawel; Jacqueline Palma; Jonathan Koenig; Xue Ping Wang; Michael Dosik; Mark H Kaplan; Charles C Chu; Sangeeta S Chavan; Richard Furie; Emilia Albesiano; Nicholas Chiorazzi; Leslie Goodwin
Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography.
Journal of biomolecular techniques : JBT 2005;16(2):154-66.
2003: Yasushi Miura; Charles C Chu; David M Dines; Stanley E Asnis; Richard Furie; Nicholas Chiorazzi
Diversification of the Ig variable region gene repertoire of synovial B lymphocytes by nucleotide insertion and deletion.
Molecular medicine (Cambridge, Mass.) 2003;9(5-8):166-74.
2003: Dimitrios T Boumpas; Richard Furie; Susan Manzi; Gabor G Illei; Daniel J Wallace; James E Balow; Akshay Vaishnaw
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.
Arthritis and rheumatism 2003;48(3):719-27.
2003: Donato Alarcón-Segovia; James Tumlin; Richard Furie; James D McKay; Mario H Cardiel; Vibeke Strand; Robert G Bagin; Matthew D Linnik; Bonnie Hepburn
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.
Arthritis and rheumatism 2003;48(2):442-54.
2003: Vibeke Strand; Cynthia Aranow; Mario H Cardiel; Donato Alarcón-Segovia; Richard Furie; Y Sherrer; James Tumlin; D J Wallace; B Crawford
Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo.
Lupus 2003;12(9):677-86.
2002: Riikka Kokkola; Erik Sundberg; Ann-Kristin Ulfgren; Karin Palmblad; Jianhua Li; Hong Wang; Luis Ulloa; Huan Yang; Joy (Xiao-Jie) Yan; Richard Furie; Nicholas Chiorazzi; Kevin Tracey; Ulf Andersson; Helena Erlandsson Harris
High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis.
Arthritis and rheumatism 2002;46(10):2598-603.
2002: Weiqing Huang; Jayashree Sinha; Jeffrey Newman; Bhoompally Reddy; Lalbachan Budhai; Richard Furie; Akshay Vaishnaw; Anne Davidson
The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.
Arthritis and rheumatism 2002;46(6):1554-62.
2001: PA McNeeley; JS Dlott; Richard Furie; R M Jack; T L Ortel; Douglas A Triplett; Edward J Victoria; Matthew D Linnik
Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I.
Thrombosis and haemostasis 2001;86(2):590-5.
2001: Richard Furie; J M Cash; M E Cronin; R S Katz; M H Weisman; Cynthia Aranow; Michael R Liebling; N P Hudson; C M Berner; S Coutts; H A de Haan
Treatment of systemic lupus erythematosus with LJP 394.
The Journal of rheumatology 2001;28(2):257-65.
2001: PA McNeeley; G Michael Iverson; Richard Furie; J M Cash; M E Cronin; R S Katz; M H Weisman; Cynthia Aranow; Matthew D Linnik
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.
Lupus 2001;10(8):526-32.
2000: K Itoh; Eric Meffre; Emilia Albesiano; A Farber; D Dines; P Stein; Stanley E Asnis; Richard Furie; RI Jain; Nicholas Chiorazzi
Immunoglobulin heavy chain variable region gene replacement As a mechanism for receptor revision in rheumatoid arthritis synovial tissue B lymphocytes.
The Journal of experimental medicine 2000;192(8):1151-64.
2000: Richard Furie
Dehydroepiandrosterone and biologics in the treatment of systemic lupus erythematosus.
Current rheumatology reports 2000;2(1):44-50.
2000: K Itoh; V Patki; Richard Furie; E K Chartash; RI Jain; L Lane; Stanley E Asnis; Nicholas Chiorazzi
Clonal expansion is a characteristic feature of the B-cell repetoire of patients with rheumatoid arthritis.
Arthritis research 2000;2(1):50-8.
1999: N Hirose; R Williams; A R Alberts; Richard Furie; E K Chartash; RI Jain; Cristina P Sison; Robert G Lahita; Joan T Merrill; Elena Cucurull; Azzudin E Gharavi; Lisa Sammaritano; Jane E Salmon; S Hashimoto; T Sawada; Charles C Chu; Peter K Gregersen; Nicholas Chiorazzi
A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome.
Arthritis and rheumatism 1999;42(8):1655-61.
1997: Lisa Sammaritano; S Ng; R Sobel; S K Lo; Ronit Simantov; Richard Furie; A Kaell; Roy L Silverstein; Jane E Salmon
Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis.
Arthritis and rheumatism 1997;40(11):1998-2006.
1996: R Hingorani; J Monteiro; Richard Furie; E Chartash; C Navarrete; Robert Pergolizzi; Peter K Gregersen
Oligoclonality of V beta 3 TCR chains in the CD8+ T cell population of rheumatoid arthritis patients.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(2):852-8.
1995: R Hingorani; J Monteiro; Robert Pergolizzi; Richard Furie; E Chartash; Peter K Gregersen
CDR3 length restriction of T-cell receptor beta chains in CD8+ T-cells of rheumatoid arthritis patients.
Annals of the New York Academy of Sciences 1995;756():179-82.
1995: R I Jain; Franco Fais; S Kaplan; B Sellars; R Brooks; E Chartash; Richard Furie; S Hashimoto; Nicholas Chiorazzi
IgH and L chain variable region gene sequence analyses of twelve synovial tissue-derived B cell lines producing IgA, IgG, and IgM rheumatoid factors structure/function comparisons of antigenic specificity, V gene sequence, and Ig isotype.
Autoimmunity 1995;22(4):229-43.
1994: R Jain; E Chartash; M Susin; Richard Furie
Systemic lupus erythematosus complicated by thrombotic microangiopathy.
Seminars in arthritis and rheumatism 1994;24(3):173-82.
1994: Richard Furie; T Ishikawa; Vijay Dhawan; David Eidelberg
Alternating hemichorea in primary antiphospholipid syndrome: evidence for contralateral striatal hypermetabolism.
Neurology 1994;44(11):2197-9.
1994: B Goldner; Richard Furie
Eosinophilic fasciitis associated with a monoclonal immunoglobulin.
Clinical and experimental rheumatology 1994;12(5):574.
1994: A R Alberts; R Lasonde; K R Ackerman; E K Chartash; M Susin; Richard Furie
Reversible monocular blindness complicating Churg-Strauss syndrome.
The Journal of rheumatology 1994;21(2):363-5.
1993: J C García Moncó; C M Wheeler; Jorge L Benach; Richard Furie; S A Lukehart; G Stanek; A C Steere
Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides.
Journal of the neurological sciences 1993;117(1-2):206-14.
1993: S Kaplan; K Hyman; R Brooks; M Wakai; S Hashimoto; Richard Furie; Nicholas Chiorazzi
Monoclonal IgM, IgG, and IgA human rheumatoid factors produced by synovial tissue-derived, EBV-transformed B cell lines.
Clinical immunology and immunopathology 1993;66(1):18-25.
1992: S D Kaplan; E K Chartash; R A Pizzarello; Richard Furie
Cardiac manifestations of the antiphospholipid syndrome.
American heart journal 1992;124(5):1331-8.
1992: E K Chartash; P K Good; E S Gould; Richard Furie
Septic subdeltoid bursitis.
Seminars in arthritis and rheumatism 1992;22(1):25-9.
1992: H B Fleit; C D Kobasiuk; C Daly; Richard Furie; P C Levy; Robert O Webster
A soluble form of Fc gamma RIII is present in human serum and other body fluids and is elevated at sites of inflammation.
Blood 1992;79(10):2721-8.
1991: N Kamdar; I Zanzi; S Kroop; Richard Furie; D Margouleff
Reversible functional asplenia in systemic lupus erythematosus.
Clinical nuclear medicine 1991;16(10):760-2.
1991: Richard Furie
Effects of human immunodeficiency virus infection on the expression of rheumatic illness.
Rheumatic diseases clinics of North America 1991;17(1):177-88.
1991: E S Gould; H G Potter; A Huvos; Richard Furie; K S Crystal
Case report 671: Arteriovenous malformation of the right lower extremity with associated intraosseous hemangiomatosis.
Skeletal radiology 1991;20(4):303-5.
1990: P Piliero; Richard Furie
Functional asplenia in systemic lupus erythematosus.
Seminars in arthritis and rheumatism 1990;20(3):185-9.
1990: E K Chartash; W P Given; S M Vishnubhakat; M Susin; E L Coffey; P M Farmer; J M Albanese; Mark H Kaplan; Richard Furie
L-tryptophan induced eosinophilia-myalgia syndrome.
The Journal of rheumatology 1990;17(11):1527-33.
1989: J S Reiner; Richard Furie
Cardiac tamponade as an initial manifestation of systemic lupus erythematosus.
The Journal of rheumatology 1989;16(8):1127-9.
1988: Richard Furie; E K Chartash
Tendon rupture in systemic lupus erythematosus.
Seminars in arthritis and rheumatism 1988;18(2):127-33.
1987: E S Gould; S Taylor; J B Naidich; Richard Furie; L Lane
MR appearance of bilateral, spontaneous patellar tendon rupture in systemic lupus erythematosus.
Journal of computer assisted tomography 1987;11(6):1096-7.
1980: Richard Furie; R P Cohen; B J Hartman; R B Roberts
Pasteurella multocida infection; report in urban setting and review of spectrum of human disease.
New York state journal of medicine 1980;80(10):1597-602.
1980: R H Dekruyff; Richard Furie; G W Siskind
Studies on the control of antibody synthesis. XVII. Effect of specific suppressor cells on the affinity of the antibody response by naive or primed lymphocytes.
Immunology 1980;40(2):255-64.